Note 10. Share-based Compensation:

During the nine months ended March 31, 2020 and 2019, the Company granted 0.8 million and 0.9 million stock options at weighted average grant prices of $190.80 and $173.89 and weighted average fair values of $37.01 and $34.66, respectively. During the nine months ended March 31, 2020 and 2019, the Company granted 30,858  and 56,403 restricted stock units at a weighted average fair value of $192.08 and $170.96, respectively. During the nine months ended March 31, 2020 and 2019, the Company granted 15,398 and 14,887 shares of restricted common stock shares at a weighted average fair value of $193.48 and $177.93.

Stock options for 398,320 and 263,995 shares of common stock with total intrinsic values of $48.6 million and $22.3 million were exercised during the nine months ended March 31, 2020 and 2019, respectively.

Stock-based compensation expense of $7.6 million and $5.7 million was included in selling, general and administrative expenses for the quarter ended March 31, 2020 and 2019, respectively. Stock-based compensation expense of $26.1 million and $24.2 million was included in selling, general, and administrative expenses for the nine months ended March 31, 2020 and 2019, respectively. Additionally, the company recognized $0.5 million and $1.4 million in cost of goods sold in the quarter and nine months ended March 31, 2020 respectively. As of March 31, 2020, there was $30.1 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.0 years.